Tag: University of Tennessee Research Foundation


News

Four University of Tennessee Health Science Center Faculty Named 2017 UT Research Foundation Maturation Fund Winners

|

The University of Tennessee Research Foundation (UTRF) announced its 2017 Maturation Funding recipients on December 15, 2016, granting four University of Tennessee Health Science Center faculty inventors $15,000 each to further develop their technology and answer important commercialization questions. Each year UTRF awards grants through its annual Maturation Funding program which is designed to help… Read More


News

UTHSC Awarded $500,000 from the U.S. Department of Commerce to Fund Innovative Proof-of-Concept Center, Stimulate Movement of Ideas to Market

|

The University of Tennessee Health Science Center (UTHSC) has received a nearly $500,000 i6 Challenge Award from the United States Economic Development Administration (EDA) to establish a Proof-of-Concept Center at UTHSC in partnership with Memphis Bioworks Foundation. The award was announced recently by U.S. Secretary of Commerce Penny Pritzker as part of the EDA’s 2016… Read More


News

The University of Tennessee Research Foundation Awards $15,000 Grants to Four UTHSC Faculty Members

|

Four faculty members at the University of Tennessee Health Science Center have received grants for $15,000 each from the University of Tennessee Research Foundation Maturation Funding Program. The program is designed to assist UT researchers to advance technologies that have the capacity for commercial success. The four grant recipients are Hassan Almoazen, PhD; Vanessa Morales-Tirado,… Read More


News

GTx and the University of Tennessee Research Foundation Enter Into Exclusive License Agreement to Develop SARD Drug Candidate to Treat Castration-Resistant Prostate Cancer

|

GTx, Inc. today announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor degrader (SARD) technology which potentially can degrade and inhibit all forms of androgen receptor (AR), including those resistant to current therapies, to inhibit tumor growth in… Read More